Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Psychotic Disorder in Adults
NCT05622201Phase 2Active, not recruiting
- Sponsor
- Region Örebro län
- Start
- Mar 2023
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia spectrum and other psychotic disorders comparing Rituximab with Placebo (2 arms). Primary endpoint: Proportion of responders to treatment, rated as much or very much improved with CGI-I at 12 weeks. Started Mar 2023; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
schizophrenia spectrum and other psychotic disorders
Beyond the preview
Go deeper on NCT05622201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622201.